KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Leases: 2020-2024

Historic Current Leases for Aquestive Therapeutics (AQST) over the last 5 years, with Dec 2024 value amounting to $510,000.

  • Aquestive Therapeutics' Current Leases rose 24.69% to $601,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $601,000, marking a year-over-year increase of 24.69%. This contributed to the annual value of $510,000 for FY2024, which is 30.77% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Current Leases stood at $510,000 for FY2024, which was up 30.77% from $390,000 recorded in FY2023.
  • Aquestive Therapeutics' 5-year Current Leases high stood at $899,000 for FY2021, and its period low was $255,000 during FY2022.
  • For the 3-year period, Aquestive Therapeutics' Current Leases averaged around $385,000, with its median value being $390,000 (2023).
  • In the last 5 years, Aquestive Therapeutics' Current Leases tumbled by 71.64% in 2022 and then spiked by 52.94% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Current Leases (Yearly) stood at $728,000 in 2020, then climbed by 23.49% to $899,000 in 2021, then plummeted by 71.64% to $255,000 in 2022, then spiked by 52.94% to $390,000 in 2023, then skyrocketed by 30.77% to $510,000 in 2024.